[Prospective study on nylestriol replacement therapy in postmenopausal women]

Area of Science:

• Endocrinology
• Gerontology
• Pharmacology

Background:

• Postmenopausal hormone therapy is crucial for managing symptoms and preventing diseases.
• Estriol derivatives are explored for their therapeutic potential in postmenopausal women.
• Understanding nylestriol's efficacy and safety is important for clinical application.

Purpose of the Study:

• To evaluate the effects of nylestriol on lipid profiles, bone metabolism, and climacteric symptoms in postmenopausal women.
• To assess the safety of nylestriol, particularly regarding endometrial and breast health.

Main Methods:

• A prospective, randomized study involving 283 postmenopausal women.
• Three groups received different dosages of nylestriol (2 mg/2 weeks, 1 mg/2 weeks) or placebo over a defined period.
• Evaluations included lipid profiles, bone mineral content, biochemical markers of bone turnover, Kupperman index, and endometrial histology.

Main Results:

• Nylestriol significantly increased high-density lipoprotein cholesterol and decreased low-density lipoprotein cholesterol.
• Serum alkaline phosphatase and bone turnover markers (calcium/creatinine, hydroxyproline/creatinine) were significantly reduced.
• Bone mineral content in the forearm remained stable, unlike the placebo group.
• Kupperman index scores significantly decreased, indicating relief from climacteric syndrome.
• No cases of endometrial carcinoma, atypical hyperplasia, or breast cancer were observed.

Conclusions:

• Nylestriol is effective in improving lipoprotein lipid patterns and alleviating climacteric syndrome in postmenopausal women.
• It demonstrates a beneficial effect in preventing osteoporosis.
• Nylestriol appears to be a safe therapeutic option with no significant adverse effects on the endometrium or breast.